文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

醛固酮合酶抑制联合或不联合恩格列净治疗慢性肾脏病的疗效与安全性:一项随机对照2期试验

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
PubMed 文献 · Lancet · 2023-12-15

这项跨国随机对照2期试验评估BI 690517(醛固酮合酶抑制剂)在慢性肾脏病患者中的疗效、安全性和剂量选择。在RAS抑制剂基础上,BI 690517 3 mg、10 mg、20 mg单药治疗14周使首晨尿UACR较基线分别变化-22%、-39%、-37%,安慰剂为-3%;联合恩格列净时UACR降低幅度相似。高钾血症发生率随剂量增加,肾上腺功能不全发生率为2%。

要点

  • BI 690517 3 mg、10 mg、20 mg单药治疗14周使首晨尿UACR较基线分别变化-22%、-39%、-37%,安慰剂为-3%。
  • 联合恩格列净时BI 690517产生相似的UACR降低幅度。
  • 高钾血症发生率:3 mg组10%、10 mg组15%、20 mg组18%、安慰剂组6%;大多数高钾血症无需干预(86%)。

核心结论

  • BI 690517在联合肾素-血管紧张素系统抑制和恩格列净的情况下剂量依赖性降低白蛋白尿,提示对慢性肾脏病治疗具有叠加疗效且无意外安全信号。

研究设计与样本

  • 跨国、随机、对照2期试验,纳入年龄18岁及以上、eGFR 30至小于90 mL/min/1·73 m2、UACR 200至小于5000 mg/g、血清钾4·8 mmol/L或以下、正在使用ACEI或ARB的患者。
  • 参与者先按1:1随机接受8周恩格列净或安慰剂导入,随后按1:1:1:1第二次随机接受14周每日一次BI 690517 3 mg、10 mg、20 mg或安慰剂治疗。
  • 研究参与者、研究协调员、研究者和数据协调中心对治疗分配设盲;主要终点为首晨尿UACR从基线(第二次随机)至治疗结束的变化。
  • 2022年2月18日至12月30日期间,714名导入参与者中586名被随机分配接受BI 690517或安慰剂。
  • 基线时女性33%(n=196)、男性67%(n=390)、非白人种族身份42%(n=244),平均年龄63·8岁(SD 11·3),平均基线eGFR 51·9 mL/min/1·73 m2(17·7),中位UACR 426 mg/g(IQR 205至889)。

主要发现

  • 首晨尿UACR从基线至第14周治疗结束的百分比变化:安慰剂-3%(95%CI -19至17),BI 690517 3 mg单药-22%(-36至-7),BI 690517 10 mg单药-39%(-50至-26),BI 690517 20 mg单药-37%(-49至-22)。
  • BI 690517联合恩格列净时产生相似的UACR降低幅度。
  • 研究者报告的高钾血症发生率:BI 690517 3 mg组10%(14/146)、10 mg组15%(22/144)、20 mg组18%(26/146)、安慰剂组6%(9/147),无论是否联合恩格列净。
  • 大多数高钾血症参与者无需干预(86%[72/84])。
  • 肾上腺功能不全作为特殊关注的不良事件,在436名接受BI 690517的参与者中报告7例(2%),在147名接受匹配安慰剂的参与者中报告1例(1%);研究期间无治疗相关死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Excess aldosterone accelerates chronic kidney disease progression. This phase 2 clinical trial assessed BI 690517, an aldosterone synthase inhibitor, for efficacy, safety, and dose selection. METHODS: This was a multinational, randomised, controlled, phase 2 trial. People aged 18 years or older with an estimated glomerular filtration rate (eGFR) of 30 to less than 90 mL/min/1·73 m2, a urine albumin to creatinine ratio (UACR) of 200 to less than 5000 mg/g, and serum potassium of 4·8 mmol/L or less, taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, were enrolled. Participants were randomly assigned (1:1) to 8 weeks of empagliflozin or placebo run-in, followed by a second randomisation (1:1:1:1) to 14 weeks of treatment with once per day BI 690517 at doses of 3 mg, 10 mg, or 20 mg, or placebo. Study participants, research coordinators, investigators, and the data coordinating centre were masked to treatment assignment. The primary endpoint was the change in UACR measured in first morning void urine from baseline (second randomisation) to the end of treatment. This study is registered with ClinicalTrials.gov (NCT05182840) and is completed. FINDINGS: Between Feb 18 and Dec 30, 2022, of the 714 run-in participants, 586 were randomly assigned to receive BI 690517 or placebo. At baseline, 33% (n=196) were women, 67% (n=390) were men, 42% (n=244) had a racial identity other than White, and mean participant age was 63·8 years (SD 11·3). Mean baseline eGFR was 51·9 mL/min/1·73 m2 (17·7) and median UACR was 426 mg/g (IQR 205 to 889). Percentage change in first morning void UACR from baseline to the end of treatment at week 14 was -3% (95% CI -19 to 17) with placebo, -22% (-36 to -7) with BI 690517 3 mg, -39% (-50 to -26) with BI 690517 10 mg, and -37% (-49 to -22) with BI 690517 20 mg monotherapy. BI 690517 produced similar UACR reductions when added to empagliflozin. Investigator-reported hyperkalaemia occurred in 10% (14/146) of those in the BI 690517 3 mg group, 15% (22/144) in the BI 690517 10 mg group, and 18% (26/146) in the BI 690517 20 mg group, and in 6% (nine of 147) of those receiving placebo, with or without empagliflozin. Most participants with hyperkalaemia did not require intervention (86% [72/84]). Adrenal insufficiency was an adverse event of special interest reported in seven of 436 study participants (2%) receiving BI 690517 and one of 147 participants (1%) receiving matched placebo. No treatment-related deaths occurred during the study. INTERPRETATION: BI 690517 dose-dependently reduced albuminuria with concurrent renin-angiotensin system inhibition and empagliflozin, suggesting an additive efficacy for chronic kidney disease treatment without unexpected safety signals. FUNDING: Boehringer Ingelheim.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Tuttle KR, Hauske SJ, Canziani ME, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet. 2023. PMID: 38109916. doi:10.1016/S0140-6736(23)02408-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。